3Q25 results were good with a solid 3.3% organic rent performance and recurring EPS up 8% YoY. Guidance is reconfirmed; the company is fully focused on delivering its 2027 plan on which we have good visibility considering that c.80% of the investments are secured. While rent dynamics give us comfort so far (driven mainly by indexation), we would like to see more evidence regarding demand for new developments coming. Besides the pipeline, more action on the investment front in Germany or France (...
The tariff war has eased, but with Trump, uncertainty has become a guarantee. While the macro-economic impact has been limited so far, the prolonged situation could still result in significant and long-lasting economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List. The Federal Reserve (FED) has started its easing cycle, but the final amount of interest rate cuts is uncertain. The European Central Bank (ECB) has now largely completed its interest rate cutting ...
Exor Press Release - Closing Announcement Amsterdam, 5 November 2025 EXOR ANNOUNCES THE CLOSING OF ITS NOTES OFFERING Exor N.V. announces the settlement of the previously announced offering of €600 million notes priced on 29 October 2025 with a fixed annual coupon of 3.75% and due on 5 November 2035. The notes, rated A- by S&P Global Ratings, have been listed on the Luxembourg Stock Exchange and admitted to trading on the Euro MTF Market. This press release is not, and shall not contain or constitute, an offer to sell or a solicitation of an offer to buy or subscribe for the notes, nor ...
Ahold Delhaize: Strong beat driven by one-offs Alfen: Bull bear fight continues bpost: 3Q25 results in line with INGF but miss vs consensus, FY25 outlook fine-tuned to top-end CM.com: Takeover offer from Bird Coca-Cola Europacific Partners: Refreshing D'Ieteren: Belron peer Driven Brands 3Q25 talks of lower Q4, choppiness in Collision and Direct Repair Exor: Ferrari reassures with strong 3Q25, improved guidance KPN: Strategy update reassures, largely in line, with solid cash returns expec...
Montea reported broadly in line 9m25 results, with EPRA earnings rising 22% to €83.0m and EPRA earnings per share to €3.61 vs. €3.67 expected (KBCS). EPRA EPS grew 8% excluding FBI impact. Net rental income grew 25% yoy, driven by the NL Intergamma completion, reaching €103.7m. The portfolio maintained a high occupancy of 99.8% and achieved like-for-like rental growth of 3.3% (mainly indexing). The cost of debt declined to 2.1% vs. 2.3% FY24. Montea's financial position remains solid, with LTV a...
Exor Press Release - Pricing Announcement Amsterdam, 29 October 2025 EXOR ANNOUNCES THE PRICING OF €600 MILLION NOTES MATURING IN 2035 Exor N.V. (rated A– with a stable outlook by Standard & Poor’s) announces that it has priced €600 million notes due 5 November 2035 carrying a fixed annual coupon of 3.75%, with an issue price of 99.386%. The purpose of the issue is to raise new funds for Exor’s general corporate purposes, including refinancing of existing debt. The notes will be listed on the Luxembourg Stock Exchange, admitted to trading on the Euro MTF Market, and the settlement of th...
Hyloris announced that it has entered into an exclusive license and supply agreement with Orion for Tranexamic Acid Intravenous Premix RTU (TXA RTU) in major European markets. This follows a previously announced agreement with Avenacy in the US, though we note this product, being a generic, is non-core for the company, as Hyloris' main focus is on reformulation and repurposing via the 505(b)(2) pathway. The company has not disclosed specific figures under the agreement, however it will be eligib...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.